AUROBAC THERAPEUTICS develops precision medicines targeting severe bacterial infections, particularly in acute hospital settings, by employing patient- and pathogen-targeted programs alongside innovative diagnostic strategies. The company addresses the critical issue of antimicrobial resistance, which complicates treatment and contributes to over 1.27 million deaths annually worldwide.
Funding
Funding not disclosed
Founders
Product
Problem
Severe bacterial infections, particularly in acute hospital settings, pose a significant threat due to increasing antimicrobial resistance (AMR). These infections complicate treatment, leading to high medical needs and contributing to over 1.27 million deaths annually worldwide. Healthcare-associated infections, such as acute respiratory infections, are a frequent complication of hospital care and a common source of sepsis.
Solution
AUROBAC THERAPEUTICS is a biopharmaceutical company focused on developing precision medicines to combat severe bacterial infections and their consequences in acute hospital environments. The company's R&D strategy encompasses patient- and pathogen-targeted programs designed to address both the causes and consequences of serious bacterial infections and AMR. A key component of this approach is the use of innovative diagnostic strategies aimed at facilitating patient stratification and optimizing treatment outcomes. By adopting these strategies, AUROBAC THERAPEUTICS aims to improve outcomes for patients in urgent need.
Target Audience
The primary target audience includes hospitals and healthcare providers treating patients with severe bacterial infections, particularly those with antimicrobial resistance, acute respiratory infections, and sepsis.
Features
- Patient-targeted programs for precision medicine development
- Pathogen-targeted programs to address causes and consequences of bacterial infections and AMR
- Innovative diagnostic strategies for patient stratification
- Focus on acute respiratory infections (HAP/VAP) and sepsis